SPRY (ARS Pharmaceuticals, Inc.) — Stock Analysis, Catalysts & AI Research

ARS Pharmaceuticals, Inc.

$9.90

Health CareBiotechnology

The Read: 6% post-Q1 2026 as management cited prescribing friction and costly scaling despite revenue beats.

Price

Overlays

Panel

SPRY

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

ARS Pharmaceuticals, Inc.

$9.90

Health CareBiotechnology

The Read: 6% post-Q1 2026 as management cited prescribing friction and costly scaling despite revenue beats.

Price

Overlays

Panel

SPRY

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Create your free account to unlock active Expected Moves for SPRY

Expected Moves

ARS Pharmaceuticals, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Create your free account to unlock active Expected Moves for SPRY

Expected Moves

ARS Pharmaceuticals, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow